Onset of Frontal Fibrosing Alopecia During Inhibition of Th1/17 Pathways with Ustekinumab
January 2019
in “
Dermatology Online Journal
”
TLDR Ustekinumab treatment didn't prevent frontal fibrosing alopecia.
This case study presented a 62-year-old woman who developed frontal fibrosing alopecia (FFA) while being treated with ustekinumab for psoriasis. Ustekinumab is a monoclonal antibody that inhibits the Th1 and Th17 pathways by targeting the IL-12 and IL-23 cytokines. Despite its effectiveness in treating psoriasis, the onset of FFA in this patient suggested that the Th1 and Th17 pathways might not be essential in the pathogenesis of FFA. The study concluded that inhibiting IL-12 and IL-23 was ineffective for treating this form of scarring alopecia, indicating that other mechanisms might be involved in FFA development.